These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37223302)

  • 1. Efficacy and safety of "Jollab Monzej" as a traditional persian compound medicine for the treatment of multiple sclerosis-related fatigue: A randomized placebo-controlled trial.
    Yousefnia Babaki F; Khodadoost M; Rezaeizadeh H; Naser Moghadasi A; Fahimi S; Hosseini H; Movahhed M; Gharagozli K
    Caspian J Intern Med; 2023; 14(2):257-266. PubMed ID: 37223302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial.
    Granja-Domínguez A; Hochsprung A; Luque-Moreno C; Magni E; Escudero-Uribe S; Heredia-Camacho B; Izquierdo-Ayuso G; Heredia-Rizo AM
    Braz J Phys Ther; 2022; 26(5):100449. PubMed ID: 36283240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
    Bertoglio JC; Baumgartner M; Palma R; Ciampi E; Carcamo C; Cáceres DD; Acosta-Jamett G; Hancke JL; Burgos RA
    BMC Neurol; 2016 May; 16():77. PubMed ID: 27215274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Jollab (a Saffron-Based Beverage) on Cancer-Related Fatigue in Breast Cancer Patients: A Double-Blind Randomized Clinical Trial.
    Mirzaei H; Gharehgozlou R; Heydarirad G; Fahimi S; Ghafari S; Mosavat SH; Moghani MM; Hajian P
    Complement Med Res; 2022; 29(6):437-445. PubMed ID: 35767970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does oral salbutamol improve fatigue in multiple sclerosis? A pilot placebo-controlled study.
    de Almeida GM; Scola RH; Ducci RDP; Cirino RHD; Cláudia SKK; Lorenzoni PJ; Lima PHS; de Oliveira LP; Werneck LC
    Mult Scler Relat Disord; 2020 Nov; 46():102586. PubMed ID: 33296982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue during multiple sclerosis relapse and its relationship to depression and neurological disability.
    Šabanagić-Hajrić S; Suljić E; Kučukalić A
    Psychiatr Danub; 2015 Dec; 27(4):406-12. PubMed ID: 26609654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
    Rammohan KW; Rosenberg JH; Lynn DJ; Blumenfeld AM; Pollak CP; Nagaraja HN
    J Neurol Neurosurg Psychiatry; 2002 Feb; 72(2):179-83. PubMed ID: 11796766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chen HH; Lai JN; Yu MC; Chen CY; Hsieh YT; Hsu YF; Wei JC
    Front Med (Lausanne); 2021; 8():744194. PubMed ID: 34651000
    [No Abstract]   [Full Text] [Related]  

  • 17. (-)-OSU6162 in the treatment of fatigue and other sequelae after aneurysmal subarachnoid hemorrhage: a double-blind, randomized, placebo-controlled study.
    Western E; Nordenmark TH; Sorteberg W; Sorteberg A; Karic T; Sorteberg A
    J Neurosurg; 2022 Jun; 136(6):1705-1715. PubMed ID: 34715650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
    Brown JWL; Cunniffe NG; Prados F; Kanber B; Jones JL; Needham E; Georgieva Z; Rog D; Pearson OR; Overell J; MacManus D; Samson RS; Stutters J; Ffrench-Constant C; Gandini Wheeler-Kingshott CAM; Moran C; Flynn PD; Michell AW; Franklin RJM; Chandran S; Altmann DR; Chard DT; Connick P; Coles AJ
    Lancet Neurol; 2021 Sep; 20(9):709-720. PubMed ID: 34418398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex.
    Ghajarzadeh M; Jalilian R; Eskandari G; Sahraian MA; Azimi A; Mohammadifar M
    Acta Neurol Belg; 2013 Dec; 113(4):411-4. PubMed ID: 23616230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.